There is an immediate opening for a post-doctoral fellow interested in cancer immunology research in the Department of Surgery at Thomas Jefferson University located in Center City, Philadelphia, PA. The Krampitz lab is looking for a postdoctoral fellow interested in the genetic, molecular, and immunological mechanisms of programmed cell removal. Candidates should have experience working with murine models, molecular biology, and genetics techniques, such as mouse colony management, xenograft development, animal surgery, cloning, cell culture, PCR, flow cytometry, immunostaining, immunohistochemistry, immunoblotting, sequencing, etc. The position will include co-mentroship from Dr. Geoffrey Krampitz from the Department of Surgery, Dr. Jonathan Brody from the Department of Surgery, and Dr. Scott Waldman from the Department of Immunology.
We are primarily interested in the process of programmed cell removal and the application of immune-mediated signaling for the diagnosis and treatment of cancers and surgical diseases. Major advances in cancer immunology has led to increased understanding of the critical role innate and adaptive immunity plays in the treatment of cancers. CD47 is a cell surface protein expressed on all cancer cells that acts as a “don’t eat me” signal and functions as a checkpoint inhibitor that interferes with innate and adaptive immunity. We helped establish the molecular mechanism and preclinical evidence for the efficacy of anti-CD47 immunotherapy for a number of solid and liquid tumors, which led to the creation of a company and ongoing clinical trials to bring this potential therapeutic modality to cancer patients. Clinical trials evaluating anti-CD47 therapies for cancers are demonstrating encouraging results in selected cancers. Emerging data reveals that “don’t eat me” and “eat me” signaling is critical to programmed cell removal that is not only vital for immune surveillance of cancers, but also essential to a number of other diseases. Our research focus is to identify key elements of programmed cell removal that can be targeted for clinical applications. Our main focuses are:
1. Biology of surgical peritoneal adhesion formation and developing directed therapies to prevent and ablate adhesions.
2. Targeted therapies aimed at the mechanisms of immune evasion used by disseminated cancer cells
3. Directed therapies aimed at cancer associated fibroblasts and their immune-modulating effects